These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 33011049)

  • 21. Development of dilipid polymyxins: Investigation on the effect of hydrophobicity through its fatty acyl component.
    Domalaon R; Berry L; Tays Q; Zhanel GG; Schweizer F
    Bioorg Chem; 2018 Oct; 80():639-648. PubMed ID: 30053708
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of infections caused by Gram-negative pathogens: current status on the pharmacokinetics/pharmacodynamics of parenteral and inhaled polymyxins in patients.
    Lin YW; Aye SM; Rao G; Zhou QT; Chan HK; Li J
    Int J Antimicrob Agents; 2020 Dec; 56(6):106199. PubMed ID: 33075510
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Can octapeptin antibiotics combat extensively drug-resistant (XDR) bacteria?
    Blaskovich MAT; Pitt ME; Elliott AG; Cooper MA
    Expert Rev Anti Infect Ther; 2018 Jun; 16(6):485-499. PubMed ID: 29848132
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Polymyxin susceptibility testing, interpretative breakpoints and resistance mechanisms: An update.
    Bakthavatchalam YD; Pragasam AK; Biswas I; Veeraraghavan B
    J Glob Antimicrob Resist; 2018 Mar; 12():124-136. PubMed ID: 28962863
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Resistance to polymyxins: Mechanisms, frequency and treatment options.
    Falagas ME; Rafailidis PI; Matthaiou DK
    Drug Resist Updat; 2010; 13(4-5):132-8. PubMed ID: 20843473
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The rise and spread of
    Nang SC; Li J; Velkov T
    Crit Rev Microbiol; 2019 Mar; 45(2):131-161. PubMed ID: 31122100
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical translation of polymyxin-based combination therapy: Facts, challenges and future opportunities.
    Zhang X; Guo F; Shao H; Zheng X
    J Infect; 2017 Feb; 74(2):118-130. PubMed ID: 27998750
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical Efficacy of Polymyxin Monotherapy versus Nonvalidated Polymyxin Combination Therapy versus Validated Polymyxin Combination Therapy in Extensively Drug-Resistant Gram-Negative Bacillus Infections.
    Cai B; Cai Y; Liew YX; Chua NG; Teo JQ; Lim TP; Kurup A; Ee PL; Tan TT; Lee W; Kwa AL
    Antimicrob Agents Chemother; 2016 Jul; 60(7):4013-22. PubMed ID: 27090177
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Activity of polymyxin B and the novel polymyxin analogue CB-182,804 against contemporary Gram-negative pathogens in New York City.
    Quale J; Shah N; Kelly P; Babu E; Backer M; Rosas-Garcia G; Salamera J; George A; Bratu S; Landman D
    Microb Drug Resist; 2012 Apr; 18(2):132-6. PubMed ID: 22196342
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [The action of combinations of the nonapeptide polymyxin B with antibiotics on gram-negative bacteria].
    Bairamashvili DI; Zinchenko AA; Maslin DN; Trakhanova MN; Miroshnikov AI
    Antibiot Khimioter; 1988 Aug; 33(8):591-4. PubMed ID: 2848467
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Polymyxins resistance among Gram-negative pathogens in India.
    Periasamy H; Gnanamani A
    Lancet Infect Dis; 2020 Dec; 20(12):1362-1363. PubMed ID: 33186513
    [No Abstract]   [Full Text] [Related]  

  • 32. Polymyxin Derivatives that Sensitize Gram-Negative Bacteria to Other Antibiotics.
    Vaara M
    Molecules; 2019 Jan; 24(2):. PubMed ID: 30641878
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Susceptibility of gram-negative bacteria to polymyxin B nonapeptide.
    Viljanen P; Vaara M
    Antimicrob Agents Chemother; 1984 Jun; 25(6):701-5. PubMed ID: 6331296
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular mechanisms of polymyxin resistance: knowns and unknowns.
    Baron S; Hadjadj L; Rolain JM; Olaitan AO
    Int J Antimicrob Agents; 2016 Dec; 48(6):583-591. PubMed ID: 27524102
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antimicrobial activity of the novel polymyxin derivative NAB739 tested against Gram-negative pathogens.
    Vaara M; Sader HS; Rhomberg PR; Jones RN; Vaara T
    J Antimicrob Chemother; 2013 Mar; 68(3):636-9. PubMed ID: 23134658
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Polymyxins: a review of the current status including recent developments.
    Kwa AL; Tam VH; Falagas ME
    Ann Acad Med Singap; 2008 Oct; 37(10):870-83. PubMed ID: 19037522
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Polymyxins: wisdom does not always come with age.
    Kassamali Z; Rotschafer JC; Jones RN; Prince RA; Danziger LH
    Clin Infect Dis; 2013 Sep; 57(6):877-83. PubMed ID: 23728146
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Molecular mechanisms of polymyxin resistance and detection of mcr genes.
    Mlynarcik P; Kolar M
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2019 Feb; 163(1):28-38. PubMed ID: 30439931
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mechanisms of Polymyxin Resistance.
    Moffatt JH; Harper M; Boyce JD
    Adv Exp Med Biol; 2019; 1145():55-71. PubMed ID: 31364071
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Structure-activity relationship studies of [1,2,5]oxadiazolo[3,4-b]pyrazine-containing polymyxin-selective resistance-modifying agents.
    Dutta S; Liu N; Gao Y; Beck L; Wang X
    Bioorg Med Chem Lett; 2022 Sep; 72():128878. PubMed ID: 35788034
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.